Last updated: May 29, 2026
Suppliers for Drospirenone and Ethinyl Estradiol APIs, Intermediates, and Finished-Drug Components
Who supplies drospirenone and ethinyl estradiol in the US and EU?
Suppliers for drospirenone + ethinyl estradiol span (1) API makers for each active ingredient, (2) intermediate and stereochemistry-capable chemical manufacturers that feed API synthesis, and (3) contract manufacturers for oral combination tablets. In practice, the supply chain is split by geography and regulatory track record: API production is concentrated among a smaller set of global facilities with validated GMP history, while finished-dose manufacturing is often performed by branded or generic CMO partners with NDA/ANDA-ready tablet lines.
API-level procurement is typically the gating item for combination products because drospirenone’s steroid backbone synthesis drives step count, cost, and impurity control. Ethinyl estradiol (EE2) synthesis is comparatively more standardized but still requires tight impurity profiles, especially around residual solvents, genotoxic impurities, and precursor-related impurities.
What companies make drospirenone APIs and key intermediates?
Drospirenone API supply is concentrated in manufacturers with steroid chemistry capacity and robust analytical packages (HPLC impurity panels, residual solvent control, polymorph and crystal form control, and stability-indicating methods). Common intermediate categories include:
- steroid core formation intermediates (cyclization and oxidation steps)
- halogenated or activated electrophiles used in late-stage functionalization
- purification intermediates that enable impurity removal in the final 2 to 3 campaigns
Practically relevant supplier type: global steroid-specialty API manufacturers and multi-product generic API plants that qualify for women’s health portfolios.
What companies make ethinyl estradiol (EE2) APIs?
EE2 API suppliers similarly tend to be global API manufacturers with steroid chemistry capability plus high discipline around genotoxic impurity risk management for estrogenic products. Intermediate streams typically include:
- estrone/estradiol conversion intermediates
- acetylene/alkyne introduction or ethynylation-capable routes (depending on manufacturing family)
- finishing hydrogenation and oxidation control to set impurity spectrum
What suppliers provide finished-dose combination tablets (drospirenone/ethinyl estradiol)?
Finished-dose manufacturers supply either:
- branded product sites (for originator labels), or
- CMO/contract tablet lines supporting ANDA launches, including blister and unit-dose packing.
Tablet formulation supply chain constraints for this combination:
- uniformity of low-dose EE2 with drospirenone at tablet scale
- compatibility across excipients with estrogenic actives
- controlled dissolution and impurity carryover management
- validated cleaning and cross-contamination control due to hormone potency
How does supplier selection differ between originator and generic supply?
Originator supply tends to be higher-integrity: the originator’s preferred API route and impurity spec are locked early and aligned to clinical lot history. Generic supply must match established specifications and demonstrate bioequivalence through formulation and process control.
For drospirenone/EE2 combination tablets, generic and biosimilar-adjacent manufacturing issues are primarily:
- API impurity profile matching (not only assay)
- polymorph or crystal form consistency for drospirenone
- process impurity control during steroid chemistry scaling
- stability under accelerated conditions and photostability packaging needs
What patent and regulatory constraints shape API sourcing for drospirenone/ethinyl estradiol?
Even when patents expire, supplier selection remains constrained by regulatory control points:
- API impurity limits tied to approved ANDA specifications
- DMF-referenced manufacturing site eligibility for ANDA applicants
- facility qualification and audit history for hormone APIs
Combination products face additional scrutiny because both actives are present at once, and each active’s controlled impurity profile has to survive final blending, compression, and coating.
Practical Supplier Map: API vs Intermediate vs CMO/Finished-Dose
What does an API procurement workflow usually look like?
- API vendor qualification: GMP status, audit readiness, batch history, impurity panel comparability.
- DMF alignment: for ANDA submissions, a supplier that holds or supports an active DMF is preferred.
- Specification matching: drospirenone and EE2 specs, including water content, residual solvents, elemental impurities, and genotoxic impurity controls.
- Scale-up readiness: steroid APIs require consistent recrystallization and polishing steps.
What intermediate suppliers matter most for drospirenone?
Drospirenone’s manufacturing complexity makes intermediate consistency critical. A supplier with reliable intermediate supply and traceable impurity control is favored because final API impurity profiles are route-dependent.
What intermediate suppliers matter most for ethinyl estradiol?
EE2 route families can generate distinct impurity signatures, so intermediate supplier choice impacts final impurity spectrum. Procurement commonly focuses on:
- route stability across campaigns
- solvent and catalyst residue control
- impurity removal efficiency in final recrystallization
Sourcing Risk: What drives supply disruptions for this drug class?
Key risk drivers for estrogen-progestin combinations:
- narrow set of facilities capable of validated steroid API production
- campaign-based steroid chemistry runs that reduce spare capacity
- stringent impurity controls and batch release timelines
- regulatory audits and DMF updates that can delay qualification
For investors and licensing teams, the supply-chain concentration is a material factor. If a single intermediate bottleneck controls multiple API batches across a CMOs network, a delay can propagate into ANDA launches and fulfillment calendars.
Competitive Landscape: Who typically participates in drospirenone/EE2 supply?
At a high level, participation breaks into three buckets:
- Global generic API companies supplying drospirenone and EE2 independently to multiple finished-dose manufacturers.
- Steroid-focused specialty manufacturers that supply APIs to branded and generic entrants.
- Tablet CMOs and packagers that run blend-compress-coat and blistering under quality systems aligned to ANDA requirements.
Key Takeaways
- Drospirenone and ethinyl estradiol supply is concentrated among steroid-capable API producers with validated impurity control.
- Combination tablets require tablet-line compatibility and excipient control in addition to API qualification.
- Supplier selection is dominated by DMF alignment, impurity panel comparability, and campaign stability rather than by pricing alone.
- Supply-chain risk is driven by steroid chemistry capacity constraints and tight GMP/analytical release requirements.
FAQs
1) What types of suppliers offer drospirenone/ethinyl estradiol APIs to generic manufacturers?
Typically global GMP API manufacturers with steroid chemistry routes and supporting DMF documentation.
2) What intermediate bottlenecks most often affect drospirenone API continuity?
Route-dependent steroid intermediates that control impurity spectrum and recrystallization outcomes.
3) Are there differences in supplier qualification for drospirenone versus ethinyl estradiol?
Yes. Drospirenone has more route sensitivity on impurity profile due to later-stage functionalization and stereochemical steps.
4) What CMO capabilities are most important for drospirenone/ethinyl estradiol tablets?
Validated tablet blend uniformity, dissolution control, and hormone-active cross-contamination cleaning validation.
5) What regulatory documentation is typically required when switching API suppliers?
Batch-specific release and comparability, plus DMF or equivalent site/grade documentation aligned to ANDA or regulatory filings.
References
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026-05-29).
- U.S. Food and Drug Administration. Drug Master Files (DMFs). (Accessed 2026-05-29).
- European Medicines Agency. EudraLex Volume 4 and related GMP guidance for starting materials and APIs. (Accessed 2026-05-29).
- FDA. Guidance for Industry: ANDA Submissions and Related Requirements for Drug Products. (Accessed 2026-05-29).
